Respiratory Illness season is right around the corner and experts are urging parents to take action to protect their newborns ...

Overall, 55.8% of infants were protected by either maternal RSV vaccination, nirsevimab, or both; 14.2% of infants were ...

Ziresovir, an antiviral drug targeted at respiratory syncytial virus (RSV), was superior to placebo in reducing signs and ...

If you, for some reason, don’t get the RSV vaccine while you’re pregnant, you can (and should!) still protect your baby after ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The effectiveness of the long-acting monoclonal antibody nirsevimab (Beyfortus) against primary care visits for lower ...

Rates of sudden infant deaths increased during the covid-19 pandemic, a new analysis suggests — and altered transmission of illnesses such as respiratory syncytial virus (RSV) might be linked to ...

One of the largest contract drug manufacturing plants in the U.S. owned by Thermo Fisher Scientific over the past 10 years ...

In the 2023 to 2024 respiratory syncytial virus (RSV) season, more than half of infants were protected by maternal RSV vaccine, nirsevimab, or both, according to research published in the Sep. 26 ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infantsParis, October 9, ...

Provider recommendation for maternal vaccination or infant nirsevimab linked to higher immunization coverage. HealthDay News — In the 2023 to 2024 respiratory syncytial virus (RSV) season ...